Long-term survival of a young patient after multi-disciplinary treatment of initially inoperable stomach cancer with metastases to the liver and visceral lymph node Case report
Article Sidebar
Main Article Content
Abstract
This paper reports on a 5-year survival of a 30-year-old male patient initially diagnosed with inoperable stomach cancer with metastases to the liver and the visceral lymph node. The systemic treatment regimen (8 cycles of DCF chemotherapy) resulted in an almost complete regression and enabled implementation of a radical resection of the stomach along with the spleen. Eight months into the treatment, the disease progressed producing several metastatic lesions to the liver. The patient received second-line palliative chemotherapy (4 cycles of EOX) which led to a significant reduction of the lesions. This enabled hepatic metastasectomy. The patient has remained in remission for 3 years.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Jassem J, Krzakowski M, Potemski P. Nowotwory układu pokarmowego. Via Medica, Gdańsk 2014.
3. Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia kliniczna. Vol 2. Via Medica, Gdańsk 2015.
4. Polkowski W, Łacko A, Guzel Z et al. Diagnostyka i leczenie raka żołądka. Onkologia w Praktyce Klinicznej 2015; 11(suppl B): 15-23.
5. Fuchs R, Guggenberger D, Neumann U, Trautwein Ch. Nowotwory przewodu pokarmowego. Diagnostyka i leczenie. Wydanie polskie. Polkowski W. (ed.). Czelej, Lublin 2012.
6. Orditura M, Galizia G, Sforza V et al. Treatment of gastric cancer. World J Gastroenterol 2014; 20(7): 1635-1649.
7. Sakamoto Y, Sano T, Shimada K et al. Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007; 95: 534-539.
8. Kerkar SP, Kemp CD, Duffy A et al.: The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. Trials 2009; 10: 121. https://doi.org/10.1186/1745-6215-10-121.
9. Tao F, Lv J, Wang W, Jin K. Clinical modalities for management of gastric cancer hepatic metastasis. Int J Clin Exp Med 2015; 8(11): 19850-19858.
10. Takemura N, Saiura A, Koga R et al.: Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012; 397: 951-957.
11. Wagner AD, Grothe W, Haerting J et al.: Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909.
12. Van Cutsem E, Moiseyenko VM, Tjulandin S et al.: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.